Navigating the Biological Landscape: Barriers to Effective Theranostic Development and Delivery

Abstract

Theranostics is a novel approach that integrates diagnostic and therapeutic efficacy on a single platform, holding great promise for precision medicine by enabling real-time monitoring of disease progression and therapeutic response. Despite significant advances, the successful development and delivery of theranostic systems are critically limited by multiple biological barriers present at systemic, tissue, cellular, anatomical, and immunological levels. These barriers restrict bioavailability, target accessibility, and therapeutic efficacy, while often increasing off-target accumulation and adverse effects. This review provides a comprehensive overview of the major biological barriers encountered in theranostic development, including physiological barriers such as plasma protein binding, renal clearance, and hepatic metabolism; anatomical barriers like endothelial linings, the blood–brain barrier (BBB), and the tumor microenvironment; cellular barriers involving membrane permeability, intracellular trafficking, and endo-lysosomal entrapment; and immunological barriers such as immune recognition, inflammatory responses, and complement activation. Special emphasis is placed on the BBB, highlighting its structural complexity, transport mechanisms, and strategies such as molecular Trojan-horse technology, receptor-mediated and adsorptive-mediated transcytosis, and nanocarrier-based approaches to enhance central nervous system delivery. The review further discusses targeted delivery challenges, including receptor heterogeneity and multidrug resistance, and critically evaluates current strategies to overcome these barriers through surface functionalization, stimuli-responsive systems, biomimetic carriers, and controlled-release mechanisms. Finally, recent advances, clinical challenges, and future perspectives—including personalized theranostics, artificial intelligence—assisted design, and next-generation barrier-penetrating systems—are explored. Overall, this review aims to provide a structured understanding of biological barriers in theranostics and highlight innovative approaches to improve their translational potential.

1. Introduction

Over the past decade (2016–2026), the field of precision medicine has advanced significantly, and nanotheranostics has emerged as a promising approach that combines diagnostic imaging and targeted therapy within a single nanoscale platform. The term “theranostics” was first coined by John Funkhouser to describe the integration of diagnosis and therapy but is now widely used to refer to multifunctional systems engineered to support personalized treatment and real-time disease monitoring. By engineering materials at the nanoscale—typically between 1 and 100 nanometers—researchers can, in principle, monitor disease progression, map biomarker expression, and deliver cytotoxic, immunomodulatory, or genetic payloads with spatiotemporal control. The therapeutic tools now include lipid nanoparticles (LNPs), polymeric nanocarriers, superparamagnetic iron oxide nanoparticles (SPIONs), mesoporous silica, and bioinspired viral or exosome-based vectors. These platforms are designed to carry out complex, multi-step tasks such as circulating in the bloodstream undetected, extravasating into diseased tissue, penetrating dense stroma, gaining intracellular access, and releasing their cargo in response to specific environmental stimuli [1].

Recent developments in theranostics have greatly enhanced cancer detection and treatment. This method takes advantage of certain receptors that are overexpressed on cancer cell surfaces. To precisely deliver therapeutic and diagnostic payloads to the tumor, high-affinity ligands are made to bind these receptors [2]. Theranostics has the potential to lower systemic toxicity and off-target effects; however, these benefits vary depending on the design of the nanoparticle, disease model, targeting strategy, and patient characteristics [3]. The same ligand can be used for both imaging and treatment in nuclear medicine. This works especially well for neuroendocrine tumors (which target somatostatin receptors) and prostate cancer (which targets PSMA) [4].

Even though these systems are very well thought out and there is recent advancement in research on them, the clinical use of systemically administered nanotheranostics is a major obstacle. Meta-analyses of pharmacokinetic data reveal striking results that merely 0.7% of an intravenously injected nanoparticle dose successfully accumulates in solid tumors [5]. This inefficiency highlights a major shortcoming in historical nanomedicine design. Studies often underestimate the sequential, highly redundant biological barriers that guard human physiological homeostasis.

Upon intravenous administration, a theranostic agent is immediately subjected to physiological barriers, including dynamic plasma protein binding, rapid renal filtration, and extensive hepatic metabolism. To reach the target tissue, the carrier must cross anatomical barriers, comprising the continuous endothelial linings of healthy vasculature, the highly selective blood–brain barrier (BBB), and the largely restrictive tumor microenvironment (TME). Once the agent reaches the target tissue interstitium, it encounters cellular barriers. Agents need to escape the endo-lysosomal degradation pathway and the immunological barriers, which include recognition by the mononuclear phagocyte system (MPS), activation of the complement cascade, and the induction of systemic inflammatory responses such as Cytokine Release Syndrome (CRS) [6,7]. In order to design next-generation theranostics, an integrated understanding of the many anatomical, physiological, cellular, and immunological barriers in the body is required. Scientists, instead of overcoming these biological systems, are now focusing on working with them, for instance, using biomimetic strategies to navigate human biology more effectively and efficiently [8].

To provide a clear and structured understanding of the challenges associated with theranostic delivery, this review follows the sequential journey of a theranostic agent through the biological system. The review begins with an overview of theranostic systems and then discusses the major biological barriers encountered after systemic administration, including physiological barriers in circulation, anatomical and tissue-level barriers, cellular and immunological barriers, and challenges related to targeted delivery. Furthermore, the review highlights current engineering approaches to overcome these limitations, such as surface modification, biomimetic strategies, stimuli-responsive systems, and controlled-release technologies. In the end, translational challenges and future perspectives are discussed to outline potential directions for the development of next-generation theranostic systems.

2. Overview of Theranostic Systems

Nanoparticle-based theranostics possess diagnostic and therapeutic features. Lipid polymer-based nanoparticles show a novel theranostic system nowadays. Nanotechnology-based drug delivery systems are carefully designed and modified at the surface level to make them work better with the body.. These changes help control when and how drugs are released, lower the risk of harmful side effects in the body, and make treatments more effective overall [9]. Theranostic nanoparticles also hold a lot of potential to resolve big medical problems like multidrug resistance and adverse effects on healthy tissues, especially in areas like cancer and heart disease treatment. They also offer new ways to protect the organs from the adverse effects of drugs [10].

Lipid polymer nanoparticles are useful nanostructures as they are easy to prepare and have several important properties. They are safe for organisms and are biodegradable, which makes them good for biomedical applications. These nanoparticles can release drugs in a controlled manner and prevent the substances from breaking down in the environment. Another benefit is that they can achieve high loading efficiency for drugs [11].

There is a growing interest in small-molecule-based theranostic agents, driven by efforts to create small drug-like compounds for the diagnosis and treatment of Alzheimer’s disease (AD). These agents possess special interest as they can be effectively eliminated from the body through natural excretory pathways, have good biocompatibility and repeatability, and are comparatively easy to synthesize. Their dual diagnostic and therapeutic capabilities are possible due to their chemical structures, design approaches, and underlying mechanisms [12].

Nowadays, fluorescent-based small-molecule theranostic imaging has been used for the diagnosis of neurodegenerative diseases [13]. Congo red (CR) is an amphiphilic molecule that comprises both hydrophilic and hydrophobic components. Although it has also been utilized in light and fluorescence microscopy, CR is frequently used for the identification of amyloid fibrils in ex vivo tissue slices, especially with polarization microscopy [14].

In vitro, CR is less sensitive than Thioflavin in identifying amyloid-β fibrils, particularly at low doses. Because it can interfere with protein misfolding and aggregation processes, potentially altering the accuracy of such tests, it is not appropriate for evaluating Aβ aggregation inhibition [15]. Successful design of theranostics requires careful optimization of several factors, such as ligand affinity, pharmacokinetic profile, stability in circulation, biocompatibility, and efficient endosomal escape. Engineering approaches such as PEGylation, biomimetic coatings, and size tuning are commonly used to improve delivery efficiency. Following the overview of theranostic systems and their design principles, it is important to understand the first set of barriers encountered immediately after systemic administration. These physiological barriers affect the circulation time, biodistribution, and the ability of theranostic agents to successfully reach target tissues.

3. Physiological Barriers in Systemic Circulation

3.1. The Protein Corona and Plasma Protein Binding

The immediate physiological environment encountered by a systemically injected nanotheranostic agent is the bloodstream. Blood plasma, which comprises approximately 90% water, 7% proteins, and various solutes, acts as a non-Newtonian fluid due to the high -volume fraction of circulating erythrocytes, leukocytes, and platelets. Within milliseconds of entering this environment, the synthetic surface of the nanoparticle is masked by a highly dynamic layer of biomolecules, predominantly proteins, forming the biomolecular or protein corona (PC) [8].

The formation of the protein corona modifies the synthetic identity of the nanoparticle and pharmacokinetic profile, biodistribution, cellular interactions, and ultimate therapeutic efficacy. PC generation occurs in distinct kinetic phases driven by the Vroman effect. In this thermodynamic and kinetic phenomenon, highly abundant but lower-affinity proteins (such as serum albumin and fibrinogen) initially adsorb to the nanoparticle surface to lower the surface free energy. Over time, these initial colonizers are subsequently displaced by lower-abundance but higher-affinity proteins, such as apolipoproteins, immunoglobulins (IgG, IgM), and complement factors, forming a hard, tightly bound inner corona and a loosely associated, dynamically exchanging soft outer corona [8,9].

The precise composition and conformation of this corona are contingent upon the nanoparticle’s physicochemical properties, namely its size, morphology, surface charge (zeta potential), and hydrophobicity. The physical curvature of the nanoparticle plays a particularly vital role in protein preservation [8]).

In the area of pharmacology, “free drug hypothesis,” posits that only the unbound fraction of a drug exerts a pharmacological effect, as defined by steady-state clearance and volume of distribution models. However, in the field of nanotheranostics, the protein corona completely bypasses these standard small-molecule kinetics. The binding of specific opsonins, such as IgG or complement C3b, actively tags the nanoparticle for rapid phagocytosis by tissue-resident macrophages, severely reducing circulation half-life and preventing target accumulation. Conversely, the strategic recruitment of specific “dysopsonins” or transport proteins can inhibit immune cell recognition, resulting in prolonged circulation and facilitating transport across biological interfaces [7,11,12].

Modern biomimetic engineering adopts this phenomenon. By pre-coating nanoparticles with engineered, specially designed protein coronas, researchers can precisely control the in vivo biological identity of the carrier. For example, competitive binding studies utilizing Nuclear Magnetic Resonance (NMR) spectroscopy have revealed that transferrin and fibronectin can effectively outcompete albumin and IgG for gold nanoparticle surfaces. Pre-coating nanoparticles with a specific four-protein combination (albumin, transferrin, fibronectin, and IgG) creates a highly specific corona that selectively enhances cancer cell uptake while drastically reducing macrophage recognition. When administered to tumor-bearing models, these engineered coronas achieved an accumulation of 13 parts per million per gram of tumor tissue—equivalent to approximately 4% of the injected dose per gram—representing a 6.5-fold improvement over naked nanoparticles and a 2.6-fold improvement over traditional PEGylated formulations. This strategy harnesses natural protein adsorption processes to create smart biological interfaces that simultaneously evade immune clearance and promote active receptor targeting [4].

3.2. Renal Clearance Mechanisms and Size Thresholds

To minimize long-term systemic toxicity and facilitate safe clinical translation, an ideal theranostic agent must exhibit an efficient and predictable clearance pathway. The primary physiological routes of elimination are renal filtration and hepatic-biliary excretion, which are determined by the dimensional, electrostatic, and topological properties of the nanocarrier. The hydrodynamic diameter (HD) threshold for renal clearance, governed by glomerular endothelial cells, is typically between 6 and 8 nanometers for rigid, spherical particles. Ultrasmall nanotheranostics, such as sub-5-nanometer gold nanoclusters or specialized gadolinium-based nanodots, utilize this pathway for rapid urinary excretion, efficiently minimizing off-target body exposure and preventing heavy metal toxicity [16].

Renal filtration depends on particle density, charge, and shape, along with the size. The anionic glomerular barrier restricts highly cationic nanoparticles due to aggressive electrostatic interactions, while neutral or slightly negative particles pass through much more freely. In addition, particle density affects the excretion kinetics, and higher-density materials clear more rapidly. For instance, specific glutathione-coated silver nanoparticles show significantly higher early-stage renal clearance than similarly sized, lower-density gold equivalents [17].

To overcome the limits of very ultra small particles, researchers have developed non-covalent self-assembling nanoparticles. These dynamic systems remain stable in the tumor microenvironment to exert their therapeutic and diagnostic effects while dissociating into easily excretable small molecules in systemic circulation [18]. This approach improves targeting while reducing long-term toxicity.

3.3. Hepatic Metabolism and CYP450 Interactions

Within the hepatic lobule, the Cytochrome P450 (CYP450) superfamily of membrane-bound, heme-containing enzymes plays a central role in xenobiotic detoxification and the biotransformation of organic nanoparticle components and their released payloads [19]. CYP families 1 through 3 are responsible for nearly 80% of all oxidative metabolism and mediate the complete elimination of approximately half of all common clinical drugs in human hepatocytes. The interaction between engineered nanomaterials and hepatic metabolism is highly reciprocal and frequently toxicological [20].

The inflammatory environment induced by nanoparticles leads to a direct downregulation of both the expression and enzymatic activity of certain CYP450 isoforms, which causes a significant challenge for theranostics. Suppression of CYP450 activity results in severe drug–drug interactions, affecting the bioavailability, safety, and therapeutic index of co-administered systemic agents or the therapeutic payload [21]. On the other hand, researchers are exploiting this strategy; for instance, poly(lactic-co-glycolic) acid (PLGA) nanoparticles have been altered with galactosamine to specifically target hepatocytes and deliver natural CYP3A4 inhibitors. By locally inhibiting CYP3A4-mediated hepatic metabolism, these nanocarriers successfully increase the systemic bioavailability and therapeutic efficiency of co-administered chemotherapeutics like docetaxel, demonstrating a highly refined method of manipulating the hepatic barrier [22,23]. While physiological barriers determine the fate of theranostic systems during circulation, target-specific delivery requires overcoming structural and tissue-specific barriers. The following section, therefore, focuses on anatomical constraints and microenvironmental factors that regulate transport from blood circulation into target tissues.

3.4. Anatomical and Tissue Microenvironment Barriers

3.4.1. Endothelial Barriers

The transition from the systemic circulation into the target tissue interstitium requires traversal of the vascular endothelium, representing the critical first anatomical barrier. The structure and permeability of the endothelial barrier vary drastically depending on the physiological or pathological state of the target tissue. In healthy tissues, endothelial cells are tightly adhered via robust adherens and tight junctions, leaving intercellular gaps of approximately 2 to 6 nanometers, which firmly restrict the paracellular extravasation of macromolecules and nanoparticles [24].

It has been studied that cancer nanotheranostics have mainly been based on the Enhanced Permeability and Retention (EPR) effect. It suggests that rapid and uncontrolled tumor neoangiogenesis forms a discontinuous endothelial lining, allowing nanoparticles to enter and accumulate. Impaired lymphatic drainage further helps to retain these nanoparticles, leading to their passive buildup [25,26].

Recent advances in imaging and quantitative analysis have changed our views of the Enhanced Permeability and Retention effect in cancer. Earlier, it was believed that nanoparticles passively enter tumors through large gaps between blood vessel cells. However, recent studies show that such inter-endothelial gaps occur at an extremely low rate (only about 0.048% of the vessel surface) in certain tumor models, and most transport actually occurs through transcytosis, an active cellular process that can contribute substantially to nanoparticle entry in solid tumors [25,27,28]. These studies indicate that nanoparticle entry is influenced by transport mechanisms that depend on tumor type, nanoparticle properties, and the experimental model used.

This switch is especially important in dense tumors like Pancreatic ductal adenocarcinoma, where the typical EPR effect is almost absent due to fibrosis and vascular compression. Instead of relying on passive entry, modern strategies focus on actively targeting blood vessels [24]. By attaching specific ligands (such as antibodies or aptamers) to nanoparticles that bind to endothelial markers like Intercellular Adhesion Molecule 1 (ICAM-1) or Platelet-Endothelial Cell Adhesion Molecule (PECAM), researchers can trigger receptor-mediated transcytosis and effectively transport nanoparticles into tumors [29].

3.4.2. The Blood–Brain Barrier and Blood-Tumor Barrier

The Blood–brain barrier (BBB) is one of the body’s most specialized and selectively permeable barriers, important for maintaining neurological homeostasis and protecting it from neurotoxins and pathogens. It is formed by an extensive network of tightly packed brain capillaries, ensuring that every neuron is closely supplied with blood [30].

The BBB is maintained by the Neurovascular unit, which includes specialized cerebral endothelial cells, pericytes, and astrocytes. Unlike other tissues, these endothelial cells lack pores and are sealed by tight junction proteins (like claudins and occludins), making the barrier extremely selective.

As a result, almost all large molecular drugs and most small drugs cannot enter the brain. Even lipid-soluble molecules are actively pumped out by ATP-binding cassette (ABC) efflux transporters, particularly ABCB1 (P-glycoprotein) and ABCG2 (Breast Cancer Resistance Protein), preventing their accumulation in brain tissue [31,32].

In highly aggressive brain cancer like Glioblastoma multiforme, the structure of the BBB is disrupted and forms the blood-tumor barrier. The barrier becomes heterogeneous—some tumor areas are leaky, while the outer, invasive regions remain tightly protected, which makes drug delivery inconsistent and allows tumor recurrence. To overcome both BBB and BTB, “Trojan horse” strategies are adopted, which hijack endogenous CNS transport pathways. By conjugating nanocarriers with highly specific targeting motifs—such as Angiopep-2 (which targets the overexpressed Low-density lipoprotein receptor-related protein 1, LRP-1) or RGD peptides (targeting integrins)—theranostic agents are passed transcellularly across the brain endothelium without disrupting the barrier’s critical integrity. Alternatively, physical modulation techniques have gained significant clinical attention. The application of low-intensity focused ultrasound (FUS) combined with circulating microbubbles induces localized acoustic cavitation, provides safe, reversible disassembly of tight junctions for highly targeted, transient drug delivery [31,33].

3.4.3. The Tumor Microenvironment (TME)

Once a theranostic agent crosses the blood vessel wall, it encounters a dense and tough tumor microenvironment (TME) [7]. TME is not merely a collection of cancer cells, but a dynamically evolving, stroma-rich ecosystem characterized by severe biophysical and metabolic aberrations that collectively impose a barrier to deep tumor penetration [7,33]. One major problem is high interstitial fluid pressure. In healthy tissues, excess interstitial fluid drains into the lymphatic system, maintaining a pressure gradient, helping drugs move easily from blood into tissues. But in solid tumors, rapid cell growth and excess extracellular matrix (like collagen and hyaluronic acid) create pressure that compresses blood and lymph vessels. This removes the normal pressure gradient, so nanoparticles cannot pass through efficiently and are limited to the immediate perivascular regions, failing to reach deeper tumor regions [7,34,35].

Metabolically, the TME is an extreme environment characterized by hypoxia and chronic acidosis. Poor blood supply and fast-growing cells create hypoxia, which changes tumor behavior and metabolism. This hypoxia stabilizes Hypoxia-Inducible Factor 1-alpha (HIF-1α), driving further abnormal angiogenesis, immunosuppression, and metabolic reprogramming toward anaerobic glycolysis (the Warburg effect). The excessive production of lactic acid coupled with poor vascular perfusion results in an acidic extracellular pH, often reducing from a physiological 7.4 to 6.5 or lower [33,36]. Instead of viewing this only as a barrier, newer nanotheranostics are designed to use these conditions. It is observed that transformable, stimuli-responsive nanosystems undergo localized conformational changes in response to the acidic pH, redox gradients, or hypoxic conditions of the TME. These carriers can undergo programmed size-shrinkage, charge-reversal, or the sudden exposure of latent targeting ligands, facilitating deep ECM penetration, inverting the biological filters, and ensuring highly specific, localized drug release exclusively within the tumor mass [32,37]. After traversing systemic and tissue-level barriers, theranostic agents encounter another critical challenge at the cellular level. Efficient intracellular delivery requires successful membrane interaction, cellular uptake, intracellular trafficking, and escape from degradative pathways.

3.5. Cellular Barriers: Internalization and Intracellular Trafficking

3.5.1. Cell Membrane Permeability and Endocytosis

Once localized within the target tissue interstitium, theranostic nanoparticles must breach the intracellular domain to deliver their payloads. The internalization of nanomaterials is heavily dictated by their physicochemical properties, primarily size, shape, surface charge, and specific ligand functionalization [38,39].

Direct, energy-independent non-endocytic translocation—via mechanisms such as the formation of inverted micelles, transient pore formation, or the “carpet-like” model of membrane thinning—is generally restricted to specific ultra-small constructs, cell-penetrating peptides (CPPs, such as polyarginine or HIV-TAT peptides), and direct membrane-fusing lipoplexes. However, for the vast majority of complex theranostic nanosystems, the cell membrane is entirely impermeable to direct diffusion, necessitating reliance on active, ATP-dependent vesicular transport processes [38,40,41].

The predominant mechanism of cellular uptake for nanomedicines is endocytosis, wherein the plasma membrane physically invaginates to engulf extracellular materials into discrete membrane-bound vesicles. Endocytic pathways are broadly categorized based on the size of the ingested material and the specific protein machinery mediating the invagination. Large particles, cellular debris, and aggregates generally enter via phagocytosis, a pathway predominantly restricted to specialized professional phagocytes (e.g., macrophages, neutrophils, and dendritic cells). Conversely, therapeutic nanoparticles typically utilize pinocytic pathways, which occur in nearly all mammalian cell types [38,39,40]. These pathways include:

(i).

Clathrin-Mediated Endocytosis (CME), initiated by specific receptor-ligand interactions. This leads to the intracellular recruitment of clathrin triskelions that coat and shape the invaginating vesicle (typically 100–150 nanometers in diameter) before it is pinched off from the membrane by the GTPase dynamin. Pharmacological screens frequently utilize chlorpromazine to specifically inhibit this pathway and track nanoparticle kinetics [42].

(ii).

Caveolae-Mediated Endocytosis (CvME): It is driven by caveolin proteins situated within cholesterol-rich lipid rafts, forming characteristic flask-shaped invaginations. This pathway is frequently targeted in nanomedicine design because caveosomes often bypass early fusion with lysosomes, potentially directing cargo toward the Golgi apparatus or endoplasmic reticulum, thereby avoiding immediate degradation. Inhibitors like Methyl-β-cyclodextrin, which deplete membrane cholesterol, are used to study this route.

(iii).

Macropinocytosis: An actin-dependent process involving the non-specific, bulk engulfment of large volumes of extracellular fluid and suspended particles. The plasma membrane ruffles and folds back on itself, producing large, heterogeneous vesicles (macropinosomes) up to several micrometers in diameter.

3.5.2. Endosomal and Lysosomal Entrapment

Following internalization via CME or macropinocytosis, the resulting vesicles enter a highly regulated, intracellular sorting pathway. Endo-lysosomal entrapment remains the single most critical bottleneck in the intracellular delivery of genetic and biological payloads (e.g., siRNA, mRNA, CRISPR/Cas9 plasmids). If the nanotheranostic agent fails to rupture or escape these vesicular compartments before lysosomal fusion, the delicate therapeutic payload undergoes rapid enzymatic degradation, nullifying its biological efficacy [38,40,42].

The vesicles rapidly fuse to form the Early Endosome (EE), which acts as a central cellular sorting hub. Specific receptors are recycled back to the plasma membrane, while the remaining therapeutic cargo progresses deeper into the cell. Through the action of vacuolar-type ATPases (V-ATPases), protons are actively pumped into the vesicle lumen, which drops the internal pH from physiological 7.4 to approximately 6.0–6.5. The vesicle matures into a Late Endosome (LE), characterized by further acidification (pH ~6.0) and the initiation of hydrolytic activity. Finally, the LE fuses with lysosomes, characterized by a highly acidic pH (~5.0) and an abundance of nucleases, proteases, and lipases, designed to catabolize foreign materials [39].

To overcome this profound cellular barrier, advanced “smart” nanocarriers are engineered with distinct, biochemically triggered endosomal escape mechanisms designed to breach the vesicle membrane before lysosomal degradation occurs [38,40,42].

3.5.3. Immunological Barriers: Host Defense and Toxicity

The ultimate guardian of host homeostasis against systemic foreign entities is the innate immune system. In nanotheranostics, immunological interactions represent a profound double-edged sword: while these pathways act as impenetrable biological barriers to efficient drug delivery, their unintentional or unregulated activation can trigger severe, potentially fatal adverse reactions in patients [6].

The Mononuclear Phagocyte System and the ABC Phenomenon

Immediately upon entering the bloodstream, the rapid formation of the protein corona recruits potent opsonins—principally Immunoglobulin G (IgG), Immunoglobulin M (IgM), and various complement proteins—onto the nanoparticle surface. These opsonins act as powerful molecular beacons, initiating rampant recognition by the Mononuclear Phagocyte System (MPS). The MPS comprises a vast, highly efficient network of phagocytic cells, primarily circulating monocytes and tissue-resident macrophages residing within the microvasculature of highly perfused filtering organs [6].

As nanotheranostics circulate through the liver, spleen, and bone marrow, they are subject to massive sequestration. Hepatic Kupffer cells lining the liver sinusoids efficiently phagocytize opsonized particles, while the red pulp macrophages of the spleen actively filter out rigid or uniquely shaped nanomaterials. This robust immunological clearance acts as an immense physical sink, drastically reducing the circulating half-life of the therapeutic agent and accounting heavily for the dismal 0.7% tumor accumulation rate observed clinically, although this value varies considerably depending on nanoparticle design, tumor type, and experimental model [5,24].

To circumvent MPS recognition, the predominant strategy over the last two decades has been the surface functionalization of nanoparticles with hydrophilic, non-ionic polymers, specifically Polyethylene Glycol (PEG). High-density PEGylation establishes a dense steric hydration layer that physically repels opsonin binding, theoretically rendering the nanoparticle immunologically “invisible”. However, extensive clinical use has revealed that this strategy is increasingly compromised by the Accelerated Blood Clearance (ABC) phenomenon. Successive systemic administrations of PEGylated nanoparticles routinely induce the host immune system to generate anti-PEG IgM and IgG antibodies [6]. Upon a second or third dose, these circulating antibodies bind directly to the synthetic PEG coating, resulting in hyper-accelerated immune recognition, massive complement activation, and the near-instantaneous MPS clearance of the therapeutic dose, rendering subsequent treatments completely ineffective [6].

CARPA and Cytokine Release Syndrome (CRS)

When nanotheranostic agents interact heavily with innate immune receptors, they can precipitate devastating systemic inflammatory cascades. A severe, acute clinical manifestation of this immunological barrier is Complement Activation-Related Pseudoallergy (CARPA). The rapid, massive release of C5a into the bloodstream following nanoparticle infusion triggers CARPA, which manifests as an acute, non-IgE-mediated hypersensitivity reaction. This leads to profound vasodilation, severe cardiopulmonary distress, and anaphylactic shock during intravenous administration, severely limiting the maximum tolerated dose of many nanomedicines [6].

A related, sustained, and equally dangerous barrier is Cytokine Release Syndrome (CRS), a potentially life-threatening systemic inflammatory response syndrome (SIRS). CRS is characterized by the explosive, unregulated hypersecretion of pro-inflammatory cytokines, specifically Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), and Interferon-gamma (IFN-γ), following extensive macrophage and T-cell hyperactivation by the nanocarriers. In the context of nanomedicine, particularly following the administration of targeted nano-immunotherapies, lipid nanoparticles, or radiotheranostics, patients can exhibit CRS symptoms ranging from high fevers and severe hypotension to extreme lymphopenia, respiratory failure, and multiorgan system dysfunction [43,44,45].

Temporal mapping of the immune response to specific nanoparticles reveals a highly predictable, orchestrated pathophysiological sequence. For instance, following the injection of dextran-coated superparamagnetic iron oxide nanoworms (SPIO NWs), rapid complement C3 opsonization occurs within 5 min, followed by delayed but aggressive granulocyte and macrophage uptake at 60 min. This cellular uptake results in a massive surge of plasma IL-6 and late-stage cytokine release, maximizing at approximately 6 h post-injection. Managing this life-threatening barrier requires sophisticated clinical intervention, often necessitating the prophylactic or reactive administration of cytokine-blocking monoclonal antibodies (e.g., tocilizumab for IL-6 receptor blockade) and corticosteroids to protect the patient from nanotheranostic-induced shock and immune effector cell-associated neurotoxicity syndrome (ICANS) [42,46,47,48].

4. Biological Barriers in Targeted Theranostic Delivery

The evolution of theranostics represents one of the most significant shifts in modern clinical oncology and precision medicine, moving the field away from the “one-size-fits-all” approach toward a strategy that integrates high-sensitivity diagnostic imaging with targeted therapeutic intervention on a single platform. This integration allows for the real-time monitoring of disease progression, biodistribution, and therapeutic response, providing a feedback loop that is essential for personalizing patient care. However, the transition of these complex systems from the laboratory to the clinic is frequently impeded by a series of biological barriers. These obstacles are not simply passive hurdles but rather dynamic, adaptive systems that vary across different scales—from systemic circulation and anatomical structures to the complex cellular machinery and the molecular landscape of multidrug resistance [49].

4.1. Receptor Heterogeneity and Expression Levels

Targeted theranostics relies on the premise that the “diagnostic” component can identify specific molecular markers, while the “therapeutic” component utilizes those same markers to deliver a lethal dose. This “active targeting” approach is fundamentally challenged by the inherent heterogeneity of receptor expression levels both between patients (inter-tumoral) and within a single tumor (intra-tumoral) [50,51].

Breast cancer serves as the quintessential model for understanding the impact of receptor heterogeneity on theranostic efficacy. Tumors are classified into molecular subgroups based on the expression of hormone receptors (HR) and human epidermal growth factor receptor-2 (HER2). The treatment landscape for a patient with HER2-positive breast cancer is vastly different from that of a patient with triple-negative breast cancer (TNBC), which lacks all three primary targets [52,53].

The significantly lower survival rate for TNBC patients underscores the limitations of current targeted theranostics. TNBC is characterized by high genetic instability and an aggressive phenotype, making the identification of “actionable” disease characteristics a priority. New possible targets identified through multiomics in 2024–2025 include gamma-glutamyl hydrolase (GGH), thymidylate synthase (TYMS), and the smoothened receptor (SMO), which could serve as the basis for the next generation of theranostic probes [52,53].

Active targeting is not a guarantee of improved accumulation. A critical advancement in our understanding of the nano-bio interface is the “binding site barrier”. This phenomenon occurs when a nanocarrier has an extremely high affinity for a receptor on the surface of a tumor cell. While high affinity is generally sought after, it can cause the nanoparticle to bind so strongly to the first cells it encounters near the blood vessel that it is unable to penetrate deeper into the tumor mass [7]. This results in a highly inhomogeneous distribution, where the periphery of the tumor is over-treated while the core remains untouched [53,54].

To overcome this, researchers are exploring “staged” delivery systems where the affinity is tuned to allow for a balance between cellular uptake and interstitial diffusion. Furthermore, the density of targeting ligands on the surface of the nanoparticle must be optimized; if the density is too high, steric hindrance can actually reduce the overall binding efficiency and lead to rapid clearance by the immune system [53].

Receptor expression is a dynamic process influenced by the local environment. For instance, the transferrin receptor is overexpressed in many malignant cells due to their increased iron requirements for proliferation. However, the level of expression can fluctuate based on iron availability and the cell cycle stage. Additionally, the concept of “receptor saturation” must be considered in theranostic dosing. If the dose of the targeted agent exceeds the total number of available receptors on the tumor surface, the excess agent will circulate until it is either cleared by the kidneys or sequestered by the liver, increasing the risk of off-target toxicity.

The use of real-time molecular imaging, such as PET-CT, is instrumental in assessing the presence and saturation of these targets before administering a therapeutic dose. In prostate cancer, PET imaging with agents targeting the prostate-specific membrane antigen (PSMA) ensures that only patients with high receptor expression are selected for radioligand therapy with radionuclides like Lutetium-177 (177Lu), thereby optimizing the therapeutic window [53,55].

4.2. Multidrug Resistance Mechanisms as a Delivery Barrier

Multidrug resistance (MDR) is perhaps the most significant biological barrier to the long-term success of cancer therapy. It is a complex phenotype where cancer cells survive exposure to a wide range of structurally and functionally unrelated drugs. In the context of theranostics, MDR is both a challenge to overcome and a condition that can be monitored through molecular imaging [26,56,57].

The classical mechanism of MDR involves the overexpression of ATP-binding cassette (ABC) transporters, most notably P-glycoprotein (P-gp), which actively pumps therapeutic agents out of the cell. Small-molecule chemotherapeutics often fall victim to this mechanism because they enter the cell via passive diffusion through the plasma membrane, where they are easily recognized by membrane-bound pumps [57,58,59].

Theranostic nanoparticles offer a unique solution to this problem. Because nanoparticles are typically internalized via endocytosis, they are sequestered within endosomes and lysosomes, effectively bypassing the efflux pumps located on the outer plasma membrane. This “Trojan horse” strategy allows for a significantly higher intracellular concentration of the drug. However, once the drug is released from the nanocarrier into the cytoplasm, it may still be subject to efflux unless the nanocarrier also delivers an MDR inhibitor or utilizes a co-delivery strategy to deplete cellular ATP levels [57,59,60].

MDR is not solely driven by genetic mutations; it is also a product of the TME. Hypoxia, a hallmark of solid tumors, is a primary driver of resistance to both chemotherapy and radiation. In hypoxic conditions, the effectiveness of beta-emitting radionuclides and certain drugs is reduced because their mechanism of action depends on the generation of reactive oxygen species (ROS), which requires oxygen [61]. Furthermore, the weakly acidic pH of the tumor interstitium can cause “ion trapping” of basic drugs, preventing them from crossing the cell membrane. To combat these microenvironmental barriers, theranostic systems are being engineered with stimuli-responsive materials that can alleviate hypoxia (e.g., by carrying oxygen or O₂-generating catalysts) or respond to acidity by releasing their payload only at the target site [53,60,61].

One of the most promising advancements (2024–2026) is the development of “smart” co-delivery nanocarriers. These platforms can simultaneously deliver a cytotoxic agent and an MDR reversal agent, such as a P-gp inhibitor or siRNA designed to silence resistance genes. This dual-payload approach addresses multiple survival routes in the cancer cell, reinforcing the antitumor potency and potentially postponing the adaptation process of drug resistance. Inorganic nanocarriers, such as mesoporous silica nanoparticles, are particularly well-suited for this role due to their high loading capacity and the ability to be modified for real-time imaging, allowing clinicians to track the delivery of both agents simultaneously [58,59,60]. The abovementioned sections indicate that biological barriers work as interconnected and sequential hindrances rather than isolated challenges. Therefore, effective theranostic design requires integrated engineering solutions capable of simultaneously addressing multiple barriers across systemic, tissue, cellular, and immunological levels.

5. Strategies to Overcome Biological Barriers

The fusion of the diagnostic and therapeutic capabilities into a single nanoplatform, termed theranostics, is a significant step in the development of precision medicine [62]. The clinical application of this potential of nanotechnology is based on the ability of the designed systems to traverse the challenging environment of the human body. The theranostic agent has to overcome a series of physiological hurdles after systemic administration: the immediate detection by the mononuclear phagocyte system (MPS), the hemodynamic forces in the vasculature, the selective permeability of endothelial barriers (such as the blood–brain barrier), the dense and fibrous ECM, and finally, the intracellular defensive mechanisms of the target cells [63,64]. The research carried out from 2021 to 2026 has demonstrated that the reliance on the ‘Enhanced Permeability and Retention’ effect of the nanovehicles is insufficient for the development of strong clinical efficacy [65,66]. The emphasis has been on the surface engineering, biomimetic camouflage, and stimulus-responsive dynamism of the nanovehicles to alter their biological identity to traverse the aforementioned hurdles [67]. All the important barrier strategies have been summarized in

Table 1. Comparative analysis of barrier modulation strategies.

Strategy	Key Advantages	Current Limitations	Safety and Immunological Concerns	Translational Feasibility (Status)
PEGylation (Baseline)	Extends circulation time via steric hindrance; well-established synthesis protocols.	Prone to the Accelerated Blood Clearance (ABC) phenomenon upon repeated dosing.	High risk of anti-PEG IgM/IgG antibody generation and Complement Activation-Related Pseudoallergy (CARPA).	Clinical (Standard). Widely used but increasingly limited by immune recognition.
Zwitterionic Coatings	Excellent hydration shell preventing protein fouling; avoids anti-PEG antibody responses.	Complex synthesis; stability issues in variable ionic strengths.	Generally low immunogenicity; circumvents the ABC phenomenon.	Early Clinical/Late Preclinical. Highly promising replacement for PEG.
Cell Membrane Camouflage	Unmatched immune evasion via “self” markers (e.g., CD47); enables homotypic targeting and BBB crossing.	Severe batch-to-batch variability; scalability issues in manufacturing.	Risk of triggering autoimmune responses if donor membranes are not perfectly matched or purified.	Preclinical. Highly effective in vivo, but constrained by CMC (Chemistry, Manufacturing, and Controls) challenges.
Trojan Horse (Cell-Mediated)	Exceptional BBB penetration; actively targets inflammatory/tumor sites via endogenous pathways.	Extreme complexity of cell engineering; risk of premature payload release during transit.	Potential for Cytokine Release Syndrome (CRS) if active immune cells (e.g., macrophages) hyper-activate.	Preclinical. Ex vivo manipulation makes scaling and standardization difficult.
Stimuli-Responsive (Endogenous)	Highly site-specific activation (pH, redox, enzymes); mitigates off-target systemic toxicity.	TME heterogeneity (e.g., variable acidity) leads to inconsistent and slow payload release.	Breakdown products of responsive polymers must be thoroughly evaluated for long-term toxicity.	Early Clinical. Some pH-sensitive liposomes are in trials, but complex logic-gated systems remain preclinical.
Engineered Protein Coronas	Pre-programs the nanoparticle’s biological identity; selectively enhances uptake while evading macrophages.	Hard to maintain corona stability across diverse patient metabolic profiles.	Competes with endogenous opsonins; could trigger immune clearance if the corona degrades.	Preclinical. Proof-of-concept established, but human proteomic variability limits immediate translation.
Controlled Release Mechanisms	Regulated cargo release via “gatekeeper” molecules, polymer erosion, or logic-gated structural changes	Prevents premature release and systemic toxicity; allows continuous release patterns or highly specific activation	Risk of failure to release, leading to ineffective treatment; requires complex, specific combinations of inputs for logic gates	Mesoporous silica nanoparticles (MSNPs) with polymer caps, Biodegradable PLGA matrices, and DNA origami nanocontainers

.

5.1. Surface Modification and Functionalization

The surface of a nanoparticle represents the point where the particle mostly interacts with the biological environment. It controls the formation of the “protein corona,” a coating of adsorbed serum proteins on the nanoparticle’s surface that confers a new biological identity and ultimately determines the particle’s fate [68]. The techniques for changing the nanoparticle surface range from basic protective coatings to sophisticated and advanced structures with different capabilities that allow interaction with biological transport processes.

Transitioning from PEGylation to Zwitterionic Surfaces: Zwitterionic materials (e.g., polybetaines) possess both positive and negative charges but maintain an overall neutral charge. They form a tightly bound hydration layer via strong electrostatic interactions with water molecules, which effectively resists protein fouling. Unlike PEG, zwitterionic surfaces do not trigger the anti-PEG antibody response, making them a superior alternative for prolonging circulation time without the ABC phenomenon. For some years, coating nanoparticles with polyethylene glycol (PEG) chains has been the standard for extending the half-life of nanocarriers. The steric hindrance imparted by the PEG chain reduces opsonization, resulting in the extension of the half-life of nanocarriers. Nonetheless, considerable investigation into the phenomena over time has shown a fundamental flaw in the PEG technique. The continued use of PEG-treated nanocarriers has been connected to the “Accelerated Blood Clearance” phenomenon, which is attributable to the development of anti-PEG IgM antibodies. The expedited clearance leads to the sequestering of nanocarriers in the liver and spleen, significantly reducing the therapeutic outcome with unintended changes [69].

Functionalization of Specific Barriers in Biology: Stealth coatings lengthen circulation time but do not necessarily promote accumulation. Active functionalization is required to overcome selective barriers such as mucosal linings and the Blood–Brain Barrier (BBB). The blood–brain barrier (BBB) is the most restrictive biological barrier, blocking almost all macromolecular medications and 98% of small-molecule pharmaceuticals. To address this issue, theranostic medicines are modified with ligands that target specific transport processes found on brain capillary endothelial cells. (i) The transferrin receptor (TfR): It remains a prominent target for receptor-mediated transcytosis (RMT). Recent advances, however, have moved beyond the use of endogenous transferrin, which competes with naturally occurring levels in the blood, to the use of high-affinity monoclonal antibodies or specific peptides that target TfR allosteric areas. For example, gold nanoparticles functionalized with anti-transferrin receptor antibodies have been shown to penetrate glioblastoma parenchyma more effectively [70]. (ii) Peptide Targeting: RGD peptides target integrins, whereas chlorotoxin, derived from scorpion venom, has gained attention as a promising alternative. In addition to increasing RMT, these ligands have a particular affinity for glioma cells, allowing for a dual-targeting strategy that improves BBB crossing and subsequent tumor absorption. (iii) Glucose Transporters (GLUT): Glycosylation of nanocarriers can utilize the highly expressed GLUT1 transporter to meet the metabolic needs of the brain. Nanoparticles coated with glucose or mannose derivatives can effectively “hitchhike” over the endothelial barrier [71]. (iv) Mucosal Barriers: The mucus layer provides a strong viscoelastic mesh for theranostic systems administered orally, intranasally, or locally to mucosal tissues (such as the colon or vagina) [72,73]. (v) Muco-Inert Coatings: To pass through mucus, particles must avoid sticky interactions with mucin fibers. Particles can travel quickly through the mucus pores because of the “slippery” surface created by thick coats of hydrophilic, neutrally charged polymers (usually PEG or zwitterions) before the mucus layer is removed and washed. (vi) Muco-Adhesion: Adhesion occurs once a barrier is breached or for local release. Thiolated polymers (thiomers) increase local bioavailability and carrier residence time at the absorption site by inducing disulfide linkages with the cysteine-rich subdomains of mucin glycoproteins [74,75].

Translational Feasibility and Safety Considerations: Even though successful PEGylation offers prolonged circulation times (strength), ABC and CARPA effects have become significant limitations associated with PEGylated drug formulations, when used for multiple doses (weakness). The development of zwitterionic coatings that protect against protein adsorption without inducing immunogenic reactions has now emerged as a very promising approach. This technology is currently being transferred from preclinical to clinical studies.

5.2. Stimuli-Responsive Theranostic Systems

The concept of “smart” theranostics revolves around developing systems that are dynamically sensitive to their surroundings. When these platforms are in touch with a particular stimulus at the target location, they undergo physicochemical changes such as disassembly, swelling, charge reversal, or ligand exposure (on-state). These platforms are designed to be stable and inert when in use (off-state). This spatiotemporal management is essential for overcoming the “binding site barrier” and reducing systemic toxicity.

Endogenous stimuli (to exploit the pathological microenvironment): Certain biochemical signals distinguish diseased tissues from healthy ones, particularly tumors and inflammatory areas.

(i).

pH responsiveness: The “Warburg effect” in cancer cells increases glycolysis and lactate production, acidifying the extracellular tumor microenvironment (TME, pH 6.5–6.8). Lysosomes and endosomes have much higher pH levels (4.5–6.0). This gradient is used by theranostic carriers containing proton-sponge polymers (such as polyhistidine) or acid-labile links (such as hydrazone, acetal, or imine). When these systems reach the acidic TME, they can increase absorption at the tumor site by releasing their payload or exposing a concealed targeting ligand (de-shielding). Endosomal escape is a significant barrier to nucleic acid treatments (siRNA, mRNA), which is made easier by this process.

(ii).

Enzyme-Responsiveness: The TME overexpresses particular proteases, including cathepsins and matrix metalloproteinases (MMPs), causing tissue remodeling and metastasis. This is referred to as “enzyme-responsiveness.” It is possible to design nanocarriers with enzyme-specific peptide cross-linkers that only break down or release cargo during periods of high enzymatic activity. For example, MMP-2-responsive approaches have been used to remove PEG coatings at the tumor site, revealing cell-penetrating peptides (CPPs) that promote internalization [76]. Cancer cells have significantly greater internal GSH levels (2–10 mM) than the external environment (2–10 μM), indicating redox responsiveness. Theranostic systems cross-linked with disulfide bonds allow effective intracellular release of the therapeutic component by remaining stable in circulation but rapidly degrading when internalized into the reducing cytosolic environment [77].

Exogenous stimuli (Remote Control of Therapy): Clinicians can externally stimulate theranostic processes using exogenous stimuli, providing a level of control that is unaffected by biological variability. (i) Ultrasound (US): With millimeter precision, it can penetrate deep tissue. Low-Intensity Pulsed Ultrasound (LIPUS) and High-Intensity Focused Ultrasound (HIFU) can cause drug release from microbubbles or phase-change nanodroplets by mechanical or thermal impacts. Importantly, the mechanical force of sonic cavitation can momentarily break down biological barriers, such as the BBB’s tight junctions (sonoporation), allowing co-administered medications to penetrate [78]. (ii) Light: Light-responsive devices use photothermal or photodynamic agents (photosensitizers). Recent findings in 2025 highlight the use of near-infrared II (NIR-II) light (1000–1700 nm), which scatters and is absorbed by tissues less than visible or NIR-I light. Erbium ion-encapsulated “self-illuminating” fiber-optic probes are a novel approach. When activated by NIR-II light, these probes emit luminescence to identify tumors while also converting light to heat for ablation. To enhance the barrier-permeabilization impact of the heat while minimizing collateral damage, the device incorporates a “waste-to-resource” feedback loop that recycles leftover excitation light to monitor temperature changes in real time [79]. (iii) Magnetic Fields: SPIONs provide dual-mode barrier modulation. To overcome hemodynamic resistance, an external magnetic field can physically draw particles into the target tissue and away from the blood flow (magnetic targeting). Alternating magnetic fields can also induce hyperthermia, which increases vascular permeability and makes cells more susceptible to chemotherapy [80].

Feasibility and Safety Issues Related to Translation: Stimuli-responsive systems possess the unique property of being activated in a highly specific manner, thereby minimizing their toxic effects elsewhere in the body (limitation). Tumor microenvironment (TME) variability often leads to inconsistencies in drug release, posing potential safety risks with respect to clearance of the more complex stimuli-responsive polymers. Despite these issues, however, the simpler pH-responsive liposomes are already undergoing clinical trials, whereas more complex logic gates are still at the pre-clinical stage.

5.3. Biomimetic and Cell-Derived Carriers

When the synthetic limits of “stealth” polymers became apparent, researchers turned to nature for guidance. Biomimetic techniques include utilizing cell-derived vesicles (exosomes) directly or concealing manufactured nanoparticles behind natural cell membranes. This “top-down” engineering method equips the carrier with the source cell’s intricate, crucial biological identity, allowing it to surmount difficulties using the body’s own “passcodes.”

Technology for Cell Membrane Coating: Researchers produce “pseudocells” by homogenizing natural cell membranes onto synthetic cores while retaining the donor’s antigenic profile and surface proteins. (i) Red Blood Cells (RBCs): Prolonged circulation is characterized by red blood cell membranes. They contain “self” markers like CD47, which successfully inhibits phagocytosis by interacting with macrophages’ SIRPα receptor and transmitting a message of “don’t eat me”. Recent advancements (2022–2025) have enabled hybrid coatings, such as the combination of platelet and RBC membranes. These hybrids have platelet-mimicking properties, including adherence to damaged vasculature or binding to circulating cancer cells, in addition to avoiding immune clearance [81]. (ii) Cancer Cell Membranes: Nanoparticles coated with cancer cell membranes promote homotypic targeting, allowing cancer cells to stick to their specific kind [82]. The carrier can “trick” the tumor tissue by using cell adhesion molecules (CAMs) on the membrane surface to allow for deep penetration and internalization [83]. (iii) Macrophage/leukocyte membranes: function as active transporters. Because they express integrins, they have the ability to bind to inflammatory endothelial cells and spread into tissues [84,85]. Because these coated particles may mimic leukocyte recruitment to brain tumors, they are very useful for crossing the blood–brain barrier in neuro-oncology [86].

Extracellular vesicles (Exosomes): Exosomes are naturally occurring nanoscale vesicles (30–150 nm) created by cells to facilitate intercellular communication. They are emerging as the most effective barrier-penetrating carriers due to their intrinsic biocompatibility and ability to transport cargo (miRNA, proteins) directly into the cytoplasm of target cells. (i) Engineering and Loading: Recent studies (2024–2026) focus on resilient strategies to load these vesicles with theranostic drugs. Electroporation, sonication, and surfactant treatments are aimed at encapsulating hydrophilic medicines or nucleic acids while keeping vesicle stability [87]. (ii) Surface Functionalization: Exosomes are generated with specific ligands to improve targeting. This can be conducted genetically (by transfecting parent cells to make fusion proteins such as Lamp2b-ligand) or chemically (via click chemistry on the exosome surface). For example, exosomes treated with the GE11 peptide (which targets EGFR) accumulate more in epithelial tumors than non-targeted vesicles [88]. (iii) CNS Delivery: Exosomes produced by brain endothelial cells or neural progenitor cells have distinct lipid and protein compositions that enable BBB bridging. They use receptor-mediated transcytosis routes more efficiently than synthetic liposomes, making them promising treatments for glioblastoma and neurological illnesses [89].

Feasibility and Safety Considerations: As biomimetic vectors, cell-membrane-coated nanoparticles offer unparalleled immune evasion and homotypic targeting ability (strength). However, despite the in vivo advantages of such biological vectors, the extremely high batch-to-batch variability, problems with scale-up, and the highly likelihood of autoimmune reactions due to impure donor membranes have precluded their clinical application (weakness/health safety concern).

5.4. Active and Passive Targeting Approaches

The ability of a theranostic payload to localize at the targeted site results in efficient distribution. Passive and active targeting are two distinct but complementary techniques that facilitate localization.

Development of the EPR Effect and Passive Targeting: Passive targeting focuses on the Enhanced Permeability and Retention (EPR) effect, a physiological phenomenon in which macromolecular carriers aggregate in cancer tissues due to neovasculature leakiness (fenestrations ranging from 200 to 2000 nm) and diminished lymphatic outflow. The EPR effect is strong, although it varies greatly among individuals. (i) Vascular Normalization: To reduce interstitial fluid pressure (IFP) and enhance convective flow into the tumor core, techniques for resolving EPR variability include “normalising” the tumor vasculature, such as using anti-angiogenic low-dose treatment [90,91]. (ii) TME Modulation: Enzymes such as collagenase or hyaluronidase can be added to nanoparticles to break down the ECM barrier, allowing drugs to diffuse more easily [92].

Mechanisms for Active Targeting: Once the carrier has reached the target tissue location via passive processes, active targeting increases cellular uptake and retention. (i) Ligand-ReceptorTargeting: Nanoparticles decorated with high-affinity ligands (antibodies, peptides, aptamers, and small molecules) can selectively bind to overexpressed receptors in sick cells. Folate, transferrin, EGFR, and integrins (e.g., αVβ3) are typical targets. (ii) CNS Delivery Techniques: The “Trojan Horse” idea has improved enormously. A molecular Trojan horse is a therapeutic enzyme combined with a monoclonal antibody that targets the insulin or transferrin receptor. The antibody moiety increases transcytosis by binding to the receptor on the BBB endothelium, mediating the therapeutic “passenger” to successfully cross the barrier [93]. (iii) Cellular Trojan Horses: A highly complex technology that harnesses living cells for transportation (2024–2025). Genetically modifying isolated hematopoietic stem cells (HSCs) led to the synthesis of therapeutic proteins. These cells are re-infused and mature into monocytes and macrophages, which are endowed with the ability to penetrate the blood–brain barrier, particularly towards sites of inflammation or cancer growth. After entering the brain parenchyma, they mature into microglia-like cells that release the therapeutic protein locally, resulting in an enduring, “bio-factory” therapeutic effect [94].

Feasibility and Safety Issues: Active targeting through molecular trojans increases barrier crossing capability significantly; several clinical trials of monoclonal antibody-based trojan delivery systems have already been conducted (advantages). Conversely, cell-based Trojan strategies suffer from extremely complex regulatory requirements, manufacturing difficulties, and significant safety issues, such as cytokine release syndrome (limitations); therefore, cell-mediated approaches remained limited to preclinical trials only.

5.5. Controlled Release Mechanisms

The final obstruction to efficacy is the timely release of the therapeutic cargo. Premature release induces systemic toxicity, whereas failure to release leads to ineffective treatment. (i) MSNPs: utilize “gatekeeper” molecules, such as gold nanoparticles, macrocyclic rings, or polymer caps, to shut medicament holes. These gates only open when a certain impulse is rendered (for example, when a tumor enzyme cleaves a linker), allowing the cargo to be released [95]. (ii) Degradable Polymer Matrices: Biodegradable polymers, such as PLGA and polyester, can release medicines by bulk or surface erosion. The rate of hydrolysis may be controlled by modifying the polymer composition (lactide/glycolide ratio), allowing for continuous release patterns spanning from days to weeks. Zwitterionic polymers are also being produced with biodegradable cross-linkers to ensure that they decompose into eliminable particles after delivery [96]. (iii) Logic-Gated Release: DNA origami nanostructures work as molecular gates. These nanocontainers may be configured to open only when a defined combination of inputs is recoded (e.g., “AND” gate: low pH AND presence of a certain miRNA). This level of computational control limits off-target release to practically nil, as healthy tissues are unlikely to meet the intricate logic limitations [97].

5.6. Comparative Translational Feasibility and Safety Considerations

Despite showing remarkable efficiency in overcoming biological barriers in vitro and in preclinical studies, their readiness to enter the realm of clinical applications is highly inconsistent. The major challenge in nanotheranostics lies in the ability to balance the level of sophistication required for barrier penetration with manufacturability and human safety.

The currently available methods to achieve barrier penetration include surface hydration strategies. PEGylation is regarded as the most advanced technique in terms of manufacturability and predictability of human safety profiles but suffers from safety problems, including the so-called Accelerated Blood Clearance (ABC) syndrome, and Complement Activation Related Pseudo-allergy (CARPA). For these reasons, zwitterionic coatings become the next generation candidates in nanotheranostics. They effectively avoid the anti-PEG response while preserving comparable levels of stealthiness, bringing zwitterions on the brink of phase II clinical trials.

In contrast, methods employing highly complex biological mimics—including cell-membrane camouflaging and cell-mediated “Trojan horse” delivery systems—continue to remain within the pre-clinical realm. Although the use of nanoparticle coatings based on erythrocyte and cancer-cell membranes is known for its ability to offer unique immune evasion and homotypic targeting, such technologies face numerous translational issues. In particular, high CMC standards together with great variation from batch-to-batch manufacturing, along with the risks of auto-immune reactions due to poorly prepared donor membranes, make large-scale clinical implementation difficult.

On the other hand, stimuli-responsive systems find themselves at the boundary of two worlds. Systems based on the simplest physiological stimuli, such as the pH-sensitive liposomes designed to operate in an acidic TME environment, have progressed to the early clinical trial phase. But systems relying on complex architectures, such as DNA-based logic-gates or multistimuli-responsive mesoporous silica, present a great challenge from the regulatory perspective due to their dynamic alterations in vivo. Finally, the most likely candidates for clinical translation among the described strategies would be systems that strike a fine balance between biological complexity, required for barrier crossing, and structural simplicity, necessary for consistent GMP manufacturing and immunological safety.

6. Role of Nanotechnology in Barrier Modulation

Nanotechnology is more than just shrinking things down; it involves the deliberate engineering of materials at the supramolecular scale to exhibit distinct physicochemical properties. The main design features that affect a theranostic agent’s flow dynamics, barrier permeability, and cellular contact are its size, shape, surface charge, and flexibility.

6.1. The Effects of Size, Shape, and Surface Charge

The “transport physics” of a nanoparticle inside the biological environment is determined by the interplay between its physical dimensions and electrostatic nature.

Size (a critical dimension): Is the main determinant of biodistribution and elimination. (i) Renal Clearance (<10 nm): The kidneys quickly remove particles smaller than 10 nm (the renal filtration threshold). This is typically detrimental to therapeutic retention, even if it is beneficial for diagnostic medications that require high signal-to-noise ratios and rapid clearance. However, because of their extremely low steric barrier, ultrasmall nanoparticles in this range, such as gold clusters and quantum dots, infiltrate the cancer stroma and extracellular matrix with remarkable effectiveness. (ii) Optimum window (10–100 nm) (for oncology): The particles are small enough to use the EPR effect and reach cancer tissue, yet large enough to avoid renal filtration. According to a specific study, particles with a diameter of around 50 nm have the highest efficiency for receptor-mediated endocytosis, achieving a balance between the appropriate ligand density for binding and membrane wrapping energy. (iii) Splenic filtration (above 200 nm): Larger particles are more likely to be mechanically filtered by the spleen and absorbed quickly by the liver’s Kupffer cells. Even if they could carry larger payloads, the size of the ECM mesh severely limits their ability to penetrate dense tumor tissues [98].

Shape Previously, spherical nanoparticles were chosen for their low surface energy and ease of manufacturing. However, biological systems (e.g., bacteria, viruses) frequently employ non-spherical forms (rods, filaments) for navigation.

(i) Hemodynamic Margination: Spherical particles in blood flow tend to remain in the center of the channel, a phenomenon known as laminar flow. Rod- or discoidal-shaped particles, on the other hand, move laterally toward the vessel walls (margination). This physical mechanism improves extravasation and targeting efficacy by increasing the likelihood of the particle interacting with endothelial receptors; (ii) Cellular uptake mechanics: The angle of contact with the cell membrane is determined by shape. More effective absorption occurs from rods that enter with their longitudinal axis perpendicular (90°) to the membrane than from those that enter flat [99]. High aspect ratio nanorods frequently perform better than spheres in terms of cellular absorption effectiveness because of their greater contact surface areas for ligand-receptor interaction, per a recent study (2023); (iii) Chirality: is a noteworthy new discovery. Enantiomorphic gold nano-octopods were used to demonstrate shape-dependent uptake, with D-enantiomers accumulating much more in glioblastoma cells than L-enantiomers or racemic mixes. This illustrates how the “handedness” of the nanostructure may correspond to the chirality of biological receptors.

The Zeta Potential (surface charge): (i) Cationic (Positive): Adsorption is facilitated by the strong interaction of positive particles with negatively charged proteoglycans on cell membranes. This leads to substantial absorption as well as systemic toxicity (platelet aggregation, haemolysis), as well as strong non-specific binding (fouling); (ii) Anionic (negative): Because negatively charged particles are less likely to be rejected by cell membranes and adsorb onto proteins, their circulation lengths are longer; (iv) Charge-Reversal Strategies: To combine the advantages of both, “smart” carriers employ charge-reversal designs. These particles are neutral or slightly negative (stealth) in the circulation, but they protonate and acquire a positive charge upon entering the acidic TME. Especially at the tumor location, this “switch” promotes robust membrane interaction and internalization [100].

Elasticity (the “Goldilocks” effect): The stiffness of a nanoparticle has a significant impact on its movement. Soft, malleable particles can pass through physiological holes and extracellular matrix meshes that are smaller than their hydrodynamic diameter. As a result, they can penetrate tissues more deeply than their rigid counterparts (such as silica or gold).

(i) Optimal Stiffness: On the other hand, particles that are too soft may distort and permanently adhere to ECM fibers. According to current theoretical and experimental research, diffusion rates are highest in a “Goldilocks” zone of semi-elasticity that is both flexible enough to deform over barriers and stiff enough to prevent collapse or adherence [101].

6.2. Smart Nanocarriers for Enhanced Penetration

Specific types of nanomaterials have been developed to use these concepts for barrier modification. (i) Gold nanoparticles (AuNPs): are effective theranostic agents due to their LSPR. This optical characteristic enables them to serve as contrast agents for CT and photoacoustic imaging while also acting as photothermal transducers. Their surface chemistry (thiol affinity) allows for accurate, dense functionalization with specific ligands (e.g., chlorotoxin) that enhance BBB penetration; (ii) Magnetic theranostics: relies on superparamagnetic iron oxide nanoparticles (IONPs). They provide negative contrast in MRI and may be modified by external magnetic fields to overcome biological barriers. “Ferumoxytol,” an FDA-approved iron supplement, is being repurposed as a theranostic medicine for imaging-guided immunotherapy, since it has been shown to shift macrophage polarization from pro-tumor M2 to anti-tumor M1 inside the tumor microenvironment [102]; (iii) Lipid Nanoparticles (LNPs): The success of COVID-19 mRNA vaccines has fuelled LNP research in cancer theranostics. Modern LNPs use ionizable cationic lipids (pKa ~6.5). These lipids are neutral at physiological pH (which reduces toxicity), but they become positively charged inside the acidic endosome, interacting with the endosomal membrane to enable the release of mRNA payloads into the cytoplasm [103]; (iv) DNA Nanostructures: Programmable origami allows for exact spatial structuring of ligands. Researchers can modify the precise amount and spacing of targeting molecules (such as aptamers) on the DNA surface to match the target cell’s inter-receptor spacing, increasing binding avidity and uptake efficiency [104].

6.3. Image-Guided Delivery Optimization Theranostics

The goal is to combine imaging and therapy so that the physician may direct the treatment as it progresses. This enables us to dynamically adapt the delivery to overcome problems unique to each patient. (i) Biodistribution and patient stratification: Using nuclear imaging (PET/SPECT) and radiolabeled nanocarriers (e.g., 64Cu, 89Zr, or 177Lu), the physician may determine the precise distribution of the treatment [105]. It is similar to a “companion diagnostic,” in that if the tumor has poor absorption due to obstacles such as low EPR, that patient may be warned away from that particular therapy since it is ineffective and increases toxicity. High uptake indicates effective barrier crossing and a possible positive treatment outcome; (ii) Predictive dosimetry: By analyzing a series of diagnostic images, the absorbed dose (in Greys) to the tumor and sensitive organs (kidneys and bone marrow) may be calculated. AI algorithms are already being used to assess these images and create dose maps, allowing for individualized dose planning that increases tumor dosage while keeping organ dosages safe [106]; (iii) Real-time feedback loops: Modern, sophisticated probes provide real-time data during therapy. For example, the NIR-II fiber-optic probe allows for real-time ratiometric luminescence imaging of the temperature at the target region. This enables the device to automatically adjust the laser power to ensure that a sufficient heat dosage is delivered to overcome obstacles and eliminate the tumor while avoiding carbonization and harm to nearby healthy tissues [79].

7. Preclinical and Clinical Challenges

In spite of impressive advancements in developing theranostic platforms, translating these technologies from bench-top research into clinical practice continues to be a challenge. There are many examples in which nanoscale theranostic formulations appear to be effective both in vitro and in animal models but ultimately do not produce similar findings when applied to human subjects. There are multiple factors contributing to the inability of nanoscale theranostic formulations to translate from laboratory to clinical settings, such as biological complexity, safety concerns associated with using nanotechnology in humans, uncertainty regarding the regulatory framework governing the use of nanotechnology in humans, and issues related to manufacturing. Identifying and understanding these translational barriers will be critical if the theranostic field is to continue making progress toward integrating theranostics into standard practice for precision medicine.

7.1. Translational Limitations

There is a significant challenge in developing theranostics due to inconsistent performance between preclinical studies and patient use. Nanoparticles used for theranostics are typically developed and optimized in carefully controlled laboratory environments, which do not represent the complexity of human physiology; e.g., an animal model will not provide a representative result because of many factors, including heterogeneous vasculature (blood vessel structure), an immune response to the nanoparticle, the variability of metabolism among individuals (metabolic variability) and the differences in diseased tissue or microenvironments created by specific disease processes. These challenges make for difficult-to-model conditions that have resulted in poor translation to clinical practice [5].

Preclinical models, especially murine cancer models, frequently overestimate the effectiveness of treatment from passive targeting because the degree of enhanced permeability and retention (EPR) effect observed with preclinical models will be lower in humans. A key report indicates that the average amount of injected nanoparticle to reach the disease site in humans is <1%, which shows that passive targeting methods are poorly designed [5]. The difference between anticipated and observed biodistribution affects the reliability of animal models in the production of theranostic agents. Another barrier to translation is inter-patient variability; heterogeneous populations express different amounts of every receptor, respond to different immune stimuli, have different levels of disease progression, and have varied rates of elimination. The existence of this variability makes developing theranostic agents that will work in all patients extremely difficult, especially for those that are dependent upon receptor-mediated targeting [107]. Targeting strategies tailored to individuals can create improved outcomes with more complexity for regulatory and validation processes.

Pharmacodynamics and pharmacokinetics are highly variable across different species. The same nanoparticles that have long half-lives in rodents may be rapidly opsonized and eliminated in humans due to the differences in protein corona formation and mononuclear phagocytic system activity between these species. As such, dosing from animals to humans is still based on empirical data and is very high risk for failure. In addition, theranostic systems are required to optimize both imaging capabilities and drug delivery. The two objectives, however, require conflicting physicochemical properties for optimal performance. Imaging agents are described as being rapidly cleared in order to minimize background noise, while drug delivery agents require prolonged retention in vivo in order to facilitate efficacy. As a result, the difficulty in balancing these two competing goals complicates formulation development and the clinical translation of theranostic systems [108]. These problems together underscore the urgent need for new predictive technologies, including organ-on-chip technologies, advanced computational modeling, and humanized animal models that better mimic human pathology/physiological processes.

7.2. Toxicity and Biocompatibility Issues

The development of clinical theranostic nanomaterials presents numerous challenges when considering the safety of these materials. The majority of theranostic nanomaterials are composed of multiple components, which include inorganic core components, polymeric coating materials, targeting agents, and imaging agents. Because these individual components may independently contribute to their potential toxicity, assessing the potential risk associated with a theranostic nanomaterial is more complex than assessing a conventional small-molecule drug. Nanoparticles may cause oxidative stress, mitochondrial injury, and DNA damage as a result of the production of reactive oxygen species (ROS), especially with metal-based and semiconductor-based nanoparticles [109,110]. Although the effects of exposure to nanoparticles are not likely to be seen for a significant time frame in either acute or sub-chronic exposure studies, they may lead to chronic inflammation or organ toxicity as a result of extended exposure to them.

Concerns over biodistribution and persistence of certain engineered nanomaterials will continue to grow as more studies are conducted and published about how these particles may accumulate in organs, such as the liver, spleen, and lymphatic systems. This accumulation occurs through uptake by macrophages associated with the reticuloendothelial system. Long-lasting or non-digestible components from engineered nanomaterials have potential for being retained in the body for long periods of time (which could produce cumulative levels of toxicity) and pose unique challenges for using the same theranostic agents over long durations used to manage chronic diseases [111]. Immunological responses are another challenge with the use of engineered nanomaterials. Immune responses to engineered nanomaterials include activation of complement pathways, cytokine release, and hypersensitivity reactions, which are sometimes referred to as complement activation-related pseudoallergy (CARPA) [112]. Immune responses to these materials could impact their pharmacokinetics by either changing their ability to reach target tissues or resulting in unexpected side effects for patients using these products.

Assessing the toxicity of nanoparticles (NPs) presents a second set of difficulties as there are no accepted testing standards in place. Traditional cytotoxicity assays may neglect to assess NP-specific results (e.g., formation of protein corona, transport of NPs within the cell, long-term biodistribution of NPs), and the physicochemical properties of NPs (e.g., size, surface charge, degree of agglomeration) can change over time after exposure to biological environments, making it difficult to provide reproducible results and to evaluate safety [113]. Because NP theranostic systems combine diagnostic and therapeutic modalities, participants also face additional toxicity concerns due to the combination of diagnostic modalities, e.g., contrast agents, fluorophores, radionuclides, potentially requiring additional consideration regarding total exposure. Thus, a primary focus of the next generation of theranostics is to develop biodegradable, metabolizable, and/or immunologically inert materials.

7.3. Regulatory and Manufacturing Challenges

The lack of a suitable regulatory framework has hindered the widespread adoption of theranostic systems as compared to traditional drugs. Due to the complexity of these multi-component systems, there is a great deal of uncertainty in regulatory classification, which can lead to lengthy approval times and divergent standards across regions [114]. Unlike pharmaceutical drugs, which are typically single-molecule entities with a single active ingredient, theranostic systems include many different components (drugs, devices, biological materials, etc.), whose collective behavior affects their therapeutic effects. Therefore, in addition to determining the efficacy and safety of each individual component, regulatory authorities also need to assess how those components interact with each other; whether the components produce any harmful degradation products; and the way they function together [115]. Consequently, developing standardized characterization procedures for these complex systems represents a considerable challenge to regulatory authorities.

The difficulties associated with quality control and reproducibility present even greater challenges than those outlined above. Small differences in conditions such as the temperature, mixing conditions, or the purity of a precursor during the synthesis of a nanoparticle can result in large deviations from the ideal size distribution, surface chemistry, and biological performance. Compared to laboratory-scale synthesis, producing consistent quality results on a large-scale industrial basis presents many more challenges [116]. Large-scale manufacturing of nanomaterials while assuring proper control over their physicochemical characteristics requires sophisticated techniques and processes that meet Good Manufacturing Practices (GMP). The existing methodology for producing nanomaterials makes it difficult to standardize and automate the process of synthesizing them, making it challenging to produce large quantities of nanomaterials that are commercially viable [98]. In addition to the cost associated with using specialized equipment and conducting multiple purification and analytical validation steps, the large-scale manufacturing of nanomaterials is comparatively expensive.

Another concern with regulation is that there are no universally accepted metrics for evaluating the performance of theranostic nanoparticles. Commonly used pharmacology parameters (i.e., maximum tolerable dose, plasma concentration) may not adequately describe how nanoparticles behave, thus necessitating the establishment of new measurement strategies incorporating biodistribution mapping, imaging capabilities, and real-time therapeutic monitoring [117]. Additionally, monitoring post-marketing use of theranostics can be more difficult as theranostic agents could have a longer residence period than conventional injectable pharmaceutical products and therefore require longer intervals of monitoring for any delayed adverse events. These considerations will require the establishment of regulatory guidelines that adequately address the use of multifunctional nanomedicine delivery systems.

Bridging the Gap: Toward Clinical Translation

In order to overcome significant preclinical and clinical obstacles, a concerted effort is needed to advance material science, biology, engineering, and regulatory science together. Several approaches are being developed to manage the translational gap between the lab and the clinic:

• Developing predictive models that are human-relevant, such as microphysiological systems and/or computer-based simulations (AI), to better predict outcomes in humans based on data extrapolated from laboratory studies.
• Developing biodegradable and biomimetic nanoparticles/carriers designed specifically to reduce both immunogenicity and long-term accumulation (toxicity) in the body through intentional design.
• Standardizing testing methods/protocols to allow for reliable measurement of nanoparticle characteristics, including size, surface properties, and in vivo behavior, thus enabling reproducible results.
• Implementing scalable production technologies (e.g., microfluidic synthesis) that enable exactitude of production in accordance with Good Manufacturing Practice (GMP) guidelines.
• Creating harmonized regulatory guidelines that distinguish theranostics as a unique class of medical products instead of categorizing them under pre-existing categories.

As a result, theranostics can potentially progress from being viewed as experimental concepts to becoming established clinical therapies(s) within their respective categories.

8. Recent Advances and Case Studies

Theranostics has made incredible advances in recent years due to advancements in nanotechnology, molecular imaging (biomaterials engineering/precision medicine). These new types of technologies provide us the ability to create “multifunctional” platforms that allow for simultaneous diagnosis (detection) of disease, delivery of targeted therapies (treatment), and monitoring of how well those treatments are working (therapeutic efficacy). These types of “systems” that combine all three functions together are being used more and more often in the fields of oncology (cancer), neurology (neurological disorders), infectious disease, and inflammatory disorders. This demonstrates the potential of theranostics to overcome biological barriers and improve clinical efficacy through integration of diagnostic and therapeutic abilities.

8.1. Cancer Theranostics

The most commonly researched area of theranostic applications is oncology as a consequence of the requirement for precise identification of tumor location, preferential delivery of therapeutic agents, and assessment of treatment efficacy. Chemotherapeutics are not very selective, and therefore most patients receiving chemotherapy will suffer from both systemic toxicity and multiple drug resistance. Theranostic systems resolve these issues by combining an imaging agent with a therapeutic agent within one nanoscale entity. Traditional therapeutic agents (nanoparticle-based carriers such as liposomes, polymeric nanoparticles, dendrimers, and inorganic nanomaterials) have been shown to accumulate within malignant tumors by virtue of the enhanced permeability and retention (EPR effects), and have been used as both imaging and therapeutic agents for patients [118]. In addition, nanoparticles may be functionalized with ligands (antibodies, peptides, or aptamers) to enable the active targeting of overexpressed tumor cell receptors, thus enhancing the specificity of the therapeutic agent [119].

Nanocarriers that respond to different stimuli have added a major advancement to the field of theranostic therapies for cancer. These carriers contain a drug that can be released in a manner that is triggered by the tumor itself or an external trigger (e.g., an acidic pH, enzyme, redox potential, light, or heat) [120]. In addition, there are photothermal theranostic nanoparticles that contain gold nanostructures capable of generating localized heating by converting infrared light into heat; the localized heating results in the destruction of the tumor cells by heat and simultaneously may provide imaging capability. Radiotheranostics is another successful method of cancer treatment. PSMA-targeting systems that are labeled with radionuclides for imaging (e.g., Gallium-68) are then labeled with a different radionuclide for therapy (e.g., Lutetium-177), allowing healthcare workers to visualize and treat the tumor using the same vector [121]. Combining the use of a diagnostic and therapeutic modality allows for personalized oncology where the therapy is tailored to the patient based on their imaging results at the time of the procedure [122].

The limitations imposed by clinical use (due to tumor variability, immune clearance and off-target accumulation) continue to restrict the successful use of these therapies. In response, researchers are now investigating the use of biomimetic nanocarriers, including cell membrane-coated nanoparticles, which can escape recognition by the immune system and penetrate tumors more effectively [123]. These systems mimic naturally occurring structures and thus improve the length of time they circulate through the body and the efficiency with which they target specific cells. Therefore, engineered matrices or biomimetic strategies may represent an innovative approach to addressing the systemic and cellular barriers associated with the application of theranostic therapeutic agents.

8.2. Theranostics in Neurological Disorders

Because the blood–brain barrier (BBB) is highly selective and prevents the majority of diagnostic and therapeutic agents from entering, neurological diseases pose special challenges for theranostic delivery. For the treatment of conditions like multiple sclerosis, glioblastoma, Parkinson’s disease, and Alzheimer’s disease, this obstacle must be removed. Delivery systems enabled by nanotechnology have demonstrated great promise in promoting BBB transport. Receptor-mediated transcytosis can be used by nanoparticles designed with surface ligands that target insulin, transferrin, or low-density lipoprotein receptors to penetrate the blood–brain barrier [124]. Simultaneous imaging and therapeutic action within the central nervous system are made possible by these targeted approaches.

Researchers have developed multifunctional nanoplatforms that are capable of magnetic resonance imaging (MRI), fluorescence imaging, and controlled drug release in order to track disease progression and, at the same time, deliver neuroprotective agents. An instance of this is that iron oxide nanoparticles that have been functionalized with therapeutic molecules enable MRI-guided targeted delivery to neuroinflammatory lesions. As a result, the clinicians can see the drug localization and therapeutic response simultaneously. Different polymeric and lipid-based nanoparticles are being investigated for the treatment of neurodegenerative diseases as well. These carriers not only offer protection to delicate biomolecules such as siRNA, peptides, and growth factors from enzymatic degradation but also facilitate their sustained release in the brain microenvironment [125]. Such approaches are highly beneficial in Alzheimer’s disease, where, in addition to the very early diagnosis, continuous therapeutic interventions will be indispensable to slow down the disease progression.

One more exciting idea that researchers came up with is molecular “Trojan horse” systems, where drugs are chemically linked to antibodies that naturally cross the BBB. These modified antibodies serve as perfect self, packed double diagnostic and therapeutic “kits, “ enabling one to picture (image) tumor/drug distribution and treatment simultaneously in brain tumors and neurodegenerative disorders [126]. All of these improvements, if taken together, show how theranostics has the potential to revolutionize the treatment of neurological disorders by providing the means for early diagnosis, delivery of the medication to the intended target, and follow-up of the disease over time features that are very challenging to achieve with traditional drug treatments.

8.3. Infectious and Inflammatory Diseases

While theranostic research is mainly focused on cancer and neurology, infectious and inflammatory diseases are revealing themselves as major new application fields, especially within the framework of antimicrobial resistance and chronic immune-mediated disorders. Nanoparticle-based theranostic antimicrobial agents can simultaneously detect pathogens and selectively degrade the targeted microbe. As an example, silver nanoparticles possess great antimicrobial properties, and, at the same time, they can be used as optical or electrochemical sensors to quickly identify pathogens [127]. These types of solutions are highly beneficial in the fight against multidrug-resistant bacteria, where quick diagnosis and targeted treatment are of utmost importance.

Nanotechnology-based platforms that can find bacterial toxins or inflammatory biomarkers can also cause drug release at specific sites. This lowers the amount of antibiotics that are absorbed into the body and slows the development of resistance [128]. These responsive systems combine sensing and therapy into a closed-loop system, which makes antimicrobial treatment more precise. Recent research has investigated theranostic nanoplatforms for the management of viral infections and sepsis. These systems use biosensing elements to find pathogen-associated molecular patterns and start therapeutic responses like targeted drug release or photothermal destruction [129]. Rapid-response theranostics demonstrate considerable potential for controlling new infectious diseases and pandemics.

Imaging-guided therapy is also helpful for inflammatory diseases like rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease. Nanoparticles engineered to target inflammatory cells can administer anti-inflammatory medications while concurrently visualizing disease loci through fluorescence or MRI-based techniques. This enables clinicians to monitor therapeutic efficacy. These applications underscore the growing applicability of theranostics beyond oncology, illustrating its adaptability in tackling various pathological conditions marked by intricate biological barriers and diverse disease mechanisms.

8.4. Convergence of Technologies Driving Modern Theranostics

Perhaps most notably, one of the hallmarks of recent advances is the confluence of various enabling technologies. For instance, breakthroughs in materials science have led to the creation of smart nanocarriers whose size, shape, and surface charge can be adjusted. Thus, the nanocarriers can overcome bodily barriers more effectively. On the other hand, progress in molecular imaging, such as PET, MRI, and multimodal imaging, has made it possible to detect diseases with greater sensitivity and at a more precise location. Moreover, artificial intelligence (AI) and computational modeling are gradually being integrated into theranostic research that matches the set criteria through the prediction of pharmacokinetics, biodistribution, and target interactions. Not only do such technologies identify the most efficient nanosystems in a shorter time, but they also reduce experimental costs and thus the time that elapses before the achievement of clinical translation. In addition, an important development in the field is the concept of personalized theranostics, where an individual’s therapeutic strategies are entirely based on his/her molecular fingerprint and imaging features. Personalized theranostics aligns with the approach of precision medicine, where a doctor can easily tell from a patient’s molecular profile what drug to administer rather than from a generalized drug protocol.

9. Future Perspectives and Emerging Trends

Currently, the area of theranostics is at a critical stage of development. As synthetic biology, artificial intelligence, and sophisticated nanotechnology combine, these systems evolve from “passive drug carriers” to “autonomous medical machines.” The following themes are expected to evolve from research concepts to treatment instruments during the next five years (2026–2030).

9.1. Tailored Theranostic Methods

EPR, BBB permeability, and enzymatic profiles are examples of dynamic biological barriers that vary greatly across people and even across many metastatic lesions within the same patient. Personalized theranostics is the way of the future. The ‘Theranostic Genome’ concept attempts to link a patient’s genetic composition to how they are expected to react to specific nanocarriers, just as pharmacogenomics tailors medications to genetic profiles. This entails identifying genetic markers that predict immune clearance rates, receptor expression levels, and barrier permeability. Integration of Liquid Biopsy: Theranostics will allow for real-time monitoring of barrier development by combining liquid biopsy, which detects circulating tumor DNA or exosomes [130]. If a cancer becomes resistant or its receptor profile changes, the theranostic drug can be changed or re-engineered in real time. Patient-Specific Formulations: Advances in microfluidics and 3D printing may make it possible to produce personalized nanocarriers at the point of care. Based on biopsy and imaging data, a customized combination of ligands and payloads may be assembled on demand to address each patient’s specific biological barrier profile.

9.2. Artificial Intelligence in Theranostic Design

AI is evolving from a supplementary tool to a primary source of innovation and creativity; its applications are summarized in

Table 2. Summary of preclinical, clinical, and translational challenges in theranostic development with prospective bridging strategies.

Challenge Category	Specific Biological/Technical Barrier	Impact on Clinical Translation	Prospective Bridging Strategies
Translational Limitations	Discrepancies between preclinical murine models and human physiology (e.g., overestimation of the EPR effect); conflicting physicochemical requirements for imaging versus therapeutic agents.	Suboptimal clinical efficacy, with less than 1% of injected nanoparticles reaching the target site; complex formulation development.	Integration of human-relevant predictive models, including organ-on-chip technologies, advanced AI simulations, and humanized animal models.
Toxicity and Biocompatibility	Multi-component complexity inducing oxidative stress, ROS generation, and immune hypersensitivity (e.g., CARPA); chronic accumulation in the reticuloendothelial system.	Potential for long-term organ toxicity; unpredictable pharmacokinetics and altered biodistribution; lack of reproducible safety evaluations.	Development of biodegradable, metabolizable, or immunologically inert biomimetic nanocarriers; standardization of rigorous in vivo testing protocols.
Regulatory and Manufacturing	Absence of unified regulatory frameworks for multi-component systems; difficulties in achieving GMP compliance and mitigating batch-to-batch variability during large-scale synthesis.	Prolonged clinical approval timelines; divergent international standards; restricted commercial viability due to high manufacturing costs.	Implementation of automated, scalable production technologies (e.g., microfluidic synthesis); establishment of harmonized regulatory guidelines for theranostics.

and

Table 3. AI applications in theranostic development.

Application Domain	AI/ML Technique	Function	Impact on Development
Target Discovery	Deep Learning, NLP	Identify novel tumor antigens	Discovery of targets previously considered “undruggable”
Carrier Design	GANs, Diffusion Models	Generate novel lipid/polymer structures	Optimization of LNP stability and payload protection
Predictive Dosimetry	U-Net CNNs, Voxel S-values	Automate segmentation; predict dose maps	Personalized treatment planning; reduced toxicity risk
Patient Stratification	Radiomics, Federated Learning	Correlate image features with response	Selection of patients most likely to benefit from specific theranostics

.

Material Discovery using Generative AI: Traditional trial-and-error synthesis is costly and time-consuming. Large datasets of chemical structures and biological interactions are being used to train generative AI models, including diffusion models and Generative Adversarial Networks, or GANs. These models may “hallucinate” innovative nanocarrier designs by accurately projecting the lipid ratio, polymer chain length, or ligand density required to break through a certain barrier, significantly speeding up the development process [131].

Protein Design Driven by AI: Techniques such as RFdiffusion and AlphaFold are revolutionizing the design of customized ligands. Researchers may now create de novo proteins that are identical to the structure of a target receptor, increasing binding affinity and specificity, rather than screening libraries of pre-existing peptides [132].

In Silico Trials and Digital Twins: Nanocarrier behavior can be recreated in a risk-free environment by creating “digital twins”—virtual physiological models of patients. AI algorithms can model how a certain nanoparticle will flow via hemodynamic forces, interact with the MPS, and cross the blood–brain barrier of a given “virtual patient.” This enables “in silico clinical trials,” which allow researchers to optimize dose regimens and carrier designs before treating a single animal or person [133].

9.3. Future Barrier Penetrating Systems

The ultimate goal is to create systems that actively traverse the biological environment rather than passively surviving it.

Active and Bio-Hybrid Nanorobotic: (i) Motile microrobots: The field includes developing active microrobots that can move forward, advancing beyond passive diffusion. External magnetic fields can propel magnetic helical swimmers through thick tissues. Motile animals, such as sperm or bacteria, serve as bio-hybrid systems’ engines. Bacteria-driven microrobots, for example, may actively swim toward hypoxic parts of a tumor (chemotaxis) and penetrate the extracellular matrix (ECM) via secreted enzymes in order to transport a therapeutic payload deep into the necrotic core, where passive carriers cannot. (ii) Exosome-Nanorobot Hybrids: A “cyborg” delivery system is created by combining biological exosomes with synthetic nanorobotics. These hybrids combine the payload capacity and controllability of synthetic machines with exosomes’ immunological compatibility and barrier-crossing properties. With their ability to explore and detect on their own, they are at the cutting edge of barrier-penetrating technology [134].

9.3.1. Next-Generation Viral Vectors

In gene therapy, the viral vector continues to be the most effective “nanomachine.” Natural viruses, however, encounter strong immunological defenses. AI-guided directed evolution is producing “next-generation” AAV capsids (such as AAV9 variants) with improved CNS tropism that are imperceptible to neutralizing antibodies. Non-invasive intravenous gene therapy for neurological illnesses is made possible by these vectors’ exceptional ability to pass the blood–brain barrier through receptor-mediated transport [135].

9.3.2. DNA Computing That Can Be Programmed

Molecular computers are being developed from DNA nanostructures. Multiple environmental inputs, such as pH, temperature, and certain mRNA sequences, may be sensed by these “logic-gated” devices, which then interpret the data to make a “decision” (release medicine or keep closed). By ensuring that therapy is only administered when the precise biological context is satisfied, this skill successfully solves the “off-target” barrier by enabling them to differentiate between a healthy cell and a malignant cell with nearly perfect precision [136].